Amniotic mesenchymal stem cells with robust chemotactic properties are effective in the treatment of a myocardial infarction model

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1062-1069

  Kim, Sung Whan ^a,b   Zhang, Hong Zhe ^a,b   Kim, Chae Eun ^a   Kim, Jong Min ^b   Kim, Moo Hyun ^a,b  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Amnion; Chemokine; Mesenchymal stem cells; Myocardial infarction; Transplantation

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANGIOPOIETIN 1; BETA1 INTEGRIN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CXCL1 CHEMOKINE; ENDOGLIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; THY 1 ANTIGEN; VASCULOTROPIN A;

AMNION CELL; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CAPILLARY DENSITY; CELL ADHESION; CELL MIGRATION; CELL REGENERATION; CELL STRUCTURE; CELL TRANSDIFFERENTIATION; CHEMOTAXIS; CONTROLLED STUDY; ENGRAFTMENT; FIBROBLAST; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMNION; CHEMOKINE; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; TRANSPLANTATION;

AMNIOTIC FLUID; ANIMALS; CHEMOTAXIS; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; TREATMENT OUTCOME;

EID: 84885294817     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.003     Document Type: Article

References (42)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
2. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemicmyocardiumenhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104: 1046-52.
3. Shake JG, Gruber PJ, BaumgartnerWA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73:1919-25.
4. Cho HJ, Lee N, Lee JY, et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 2007;204: 3257-69.
5. Byun KH, Kim SW. Is stem cell-based therapy going on or out for cardiac disease? Korean Circ J 2009;39:87-92.
6. Kang HJ, Kim JY, Lee HJ, et al. Magnetic bionanoparticle enhances homing of endothelial progenitor cells in mouse hindlimb ischemia. Korean Circ J 2012;42:390-6.
7. Alviano F, Fossati V, Marchionni C, et al. Term amnioticmembrane is a high throughput source formultipotent mesenchymal stemcellswith the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 2007;7:11.
8. Portmann-Lanz CB, Schoeberlein A, Huber A, et al. Placentalmesenchymal stemcells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006;194:664-73.
9. Kim SW, Zhang HZ, Guo L, et al. Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. PLoS One 2012;7:e41105.
10. Kim SW, Zhang HZ, Kim CE, An HS, Kim JM, Kim MH. Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia. Cardiovasc Res 2012;93:525-34.
11. Ringe J, Strassburg S, Neumann K, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007;101: 135-46.
12. Kim MH, Zhang HZ, Kim SW. Combined growth factors enhanced angiogenic potential of cord blood-derived mononuclear cells transplanted to ischemic limbs. J Mol Cell Cardiol 2011;51:702-12.
13. Kim MH, Jin E, Zhang HZ, Kim SW. Robust angiogenic properties of cultured human peripheral blood-derived CD31(+) cells. Int J Cardiol 2011.
14. Ii M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 2006;98:697-704.
15. Tsuji H, Miyoshi S, Ikegami Y, et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res 2010;106:1613-23.
16. Proost P, DeWolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol 1993;150:1000-10.
17. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-57.
18. Van Coillie E, Van Aelst I,Wuyts A, et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. AmJ Pathol 2001;159:1405-14.
19. Van Damme J,Wuyts A, Froyen G, et al. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J Leukoc Biol 1997;62:563-9.
20. Li A, Dubey S, VarneyML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, andmatrixmetalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
21. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as amacrophage-derivedmediator of angiogenesis. Science 1992;258:1798-801.
22. Powell Jr JA,Mousa SA.Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. J Cell Biochem 2007;102:412-20.
23. Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007;25:245-51.
24. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004;110:3300-5.
25. Huang J, Zhang Z, Guo J, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010;106:1753-62.
26. Zhang D, Fan GC, Zhou X, et al. Over-expression of CXCR4 onmesenchymal stemcells augmentsmyoangiogenesis in the infarctedmyocardium. JMol Cell Cardiol 2008;44: 281-92.
27. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-85.
28. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005;112:1128-35.
29. Kilroy GE, Foster SJ,Wu X, et al. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 2007;212:702-9.
30. Kim SW, Han H, Chae GT, et al. Successful stem cell therapy using umbilical cord blood-derivedmultipotent stemcells for Buerger's disease and ischemic limb disease animal model. Stem Cells 2006;24:1620-6.
31. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109:1543-9.
32. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bonemarrowcells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344-9.
33. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.
34. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiacmyocytes inmyocardial infarcts. Nature 2004;428:664-8.
35. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bonemarrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004;94:230-8.
36. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.
37. Mangi AA,Noiseux N, Kong D, et al.Mesenchymal stemcellsmodified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201.
38. Perks CM,McCaig C, Holly JM. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem 2000;80:248-58.
39. Desbois-Mouthon C,WendumD, Cadoret A, et al. Hepatocyte proliferation during liver regeneration is impaired inmice with liver-specific IGF-1R knockout. FASEB J 2006;20: 773-5.
40. Welch S, Plank D,Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002;90: 641-8.
41. Date T, Mochizuki S, Belanger AJ, et al. Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol Cell Physiol 2005;288:C314-20.
42. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23.